Sabby Management, LLC Acurx Pharmaceuticals, Inc. Transaction History
Sabby Management, LLC
- $3.95 Million
- Q2 2025
A detailed history of Sabby Management, LLC transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Sabby Management, LLC holds 81,892 shares of ACXP stock, worth $411,097. This represents 1.04% of its overall portfolio holdings.
Number of Shares
81,892
Previous 2,044,546
95.99%
Holding current value
$411,097
Previous $797,000
94.86%
% of portfolio
1.04%
Previous 6.36%
Shares
2 transactions
Others Institutions Holding ACXP
# of Institutions
35Shares Held
2.62MCall Options Held
62.9KPut Options Held
56.9K-
Armistice Capital, LLC New York, NY1.08MShares$5.41 Million0.01% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$1.84 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$734,9480.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA146KShares$730,5950.0% of portfolio
-
Morgan Stanley New York, NY106KShares$533,1290.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $58M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...